{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:55:11Z","timestamp":1777730111721,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00120-026-02817-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:01:43Z","timestamp":1776063703000},"page":"480-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktualisierung S3-Leitlinie zum metastasierten Prostatakarzinom\u00a0\u2013 Leitlinienempfehlungen und Expertenkonsens","Update of S3\u00a0guideline on metastatic prostate cancer\u2014guideline recommendations and expert consensus"],"prefix":"10.1007","volume":"65","author":[{"given":"Marc-Oliver","family":"Grimm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Hellmis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2817_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K. and AWMF) (2025) S3-Leitlinie Prostatakarzinom, Langversion 8.1, 2025, AWMF-Registernummer: 043-022OL. www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/. Accessed 6.3.2026"},{"key":"2817_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K. and AWMF) (2025) S3-Leitlinie Prostatakarzinom, Leitlinienreport 8.1, AWMF-Registernummer: 043-022OL. www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/. Accessed 9.3.2026"},{"issue":"2","key":"2817_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","volume":"8","author":"W Fukuokaya","year":"2025","unstructured":"Fukuokaya\u00a0W et\u00a0al (2025) Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. Eur Urol Oncol 8(2):263\u2013269","journal-title":"Eur Urol Oncol"},{"key":"2817_CR4","unstructured":"Grimm, M.O., et\u00a0al., [Treatment of metastatic hormone-sensitive prostate cancer]. Urologie, 2026."},{"key":"2817_CR5","unstructured":"Johnson&Johnson (2026) European Commission approves AKEEGA\u00ae (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1\/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC). www.jnj.com\/media-center\/press-releases\/european-commission-approves-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hormone-sensitive-prostate-cancer-mhspc. Accessed 10.3.2026"},{"issue":"22","key":"2817_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono\u00a0J et\u00a0al (2020) Olaparib for Metastatic Castration-Resistant Prostate Cancer. N\u00a0Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"10398","key":"2817_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal\u00a0N et\u00a0al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398):291\u2013303","journal-title":"Lancet"},{"issue":"18","key":"2817_CR8","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi\u00a0KN et\u00a0al (2023) Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J\u00a0Clin Oncol 41(18):3339\u20133351","journal-title":"J Clin Oncol"},{"issue":"9","key":"2817_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke\u00a0NW et\u00a0al (2022) Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid 1(9):EVIDoa2200043","journal-title":"NEJM Evid"},{"issue":"12","key":"2817_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O et\u00a0al (2021) Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N\u00a0Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"key":"2817_CR11","doi-asserted-by":"publisher","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","volume":"30","author":"JS de Bono","year":"2019","unstructured":"de Bono\u00a0JS et\u00a0al (2019) 847PD - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from \u3009\u202f4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Annals of Oncology 30:v328\u2013v329","journal-title":"Annals of Oncology"},{"issue":"5","key":"2817_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JU.0000000000003186","volume":"209","author":"KE Breen","year":"2023","unstructured":"Breen\u00a0KE et\u00a0al (2023) Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. J\u00a0Urol 209(5):918\u2013927","journal-title":"J Urol"},{"issue":"5","key":"2817_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard\u00a0CC et\u00a0al (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N\u00a0Engl J Med 375(5):443\u2013453","journal-title":"N Engl J Med"},{"issue":"14","key":"2817_CR14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro\u00a0E et\u00a0al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J\u00a0Clin Oncol 31(14):1748\u20131757","journal-title":"J Clin Oncol"},{"key":"2817_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.euros.2022.11.011","volume":"49","author":"N Mehra","year":"2023","unstructured":"Mehra\u00a0N et\u00a0al (2023) Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting. Eur Urol Open Sci 49:23\u201331","journal-title":"Eur Urol Open Sci"},{"issue":"14","key":"2817_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah\u00a0J et\u00a0al (2024) Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. J\u00a0Clin Oncol 42(14):1687\u20131698","journal-title":"J Clin Oncol"},{"issue":"11","key":"2817_CR17","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","volume":"11","author":"S Carreira","year":"2021","unstructured":"Carreira\u00a0S et\u00a0al (2021) Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP\u2011B Trial. Cancer Discov 11(11):2812\u20132827","journal-title":"Cancer Discov"},{"issue":"5_suppl","key":"2817_CR18","doi-asserted-by":"publisher","first-page":"LBA18","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","volume":"43","author":"N Agarwal","year":"2025","unstructured":"Agarwal\u00a0N et\u00a0al (2025) Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO\u20112 trial. Journal of Clinical Oncology 43(5_suppl):LBA18\u2013LBA18","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"2817_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad\u00a0F et\u00a0al (2023) Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 24(10):1094\u20131108","journal-title":"Lancet Oncol"},{"issue":"8","key":"2817_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain\u00a0M et\u00a0al (2022) Tumor Genomic Testing for \u3009\u202f4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase\u00a0III Trial PROfound (Olaparib). Clin Cancer Res 28(8):1518\u20131530","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2817_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00345-024-05188-7","volume":"42","author":"M Hommerding","year":"2024","unstructured":"Hommerding\u00a0M et\u00a0al (2024) Real-world data on the prevalence of BRCA1\/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer. World J Urol 42(1):491","journal-title":"World J Urol"},{"issue":"8","key":"2817_CR22","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1007\/s11033-023-08491-5","volume":"50","author":"K Vito\u0161evi\u0107","year":"2023","unstructured":"Vito\u0161evi\u0107\u00a0K et\u00a0al (2023) The quality of DNA isolated from autopsy formalin-fixed and formalin-fixed paraffin-embedded tissues: study of 1662 samples. Mol Biol Rep 50(8):6323\u20136336","journal-title":"Mol Biol Rep"},{"key":"2817_CR23","volume":"2017","author":"W Abida","year":"2017","unstructured":"Abida\u00a0W et\u00a0al (2017) Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol 2017:2017","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2817_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti\u00a0S et\u00a0al (2022) EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Patients with Prostate Cancer and with Respect to [(177)Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol 5(5):530\u2013536","journal-title":"Eur Urol Oncol"},{"key":"2817_CR25","unstructured":"Garje, R., et\u00a0al., Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 0(0): p. JCO-25-00007."},{"key":"2817_CR26","unstructured":"NCCN (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer, Version 2.2025. www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 6.3.2026"},{"key":"2817_CR27","unstructured":"EMA. Fachinformation Pluvicto. [Zugriff 06.03.2026]; www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pluvicto."},{"key":"2817_CR28","unstructured":"Novartis Radiopharmaceuticals GmbH (2022) Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7\u00a035a\u00a0SGB\u00a0V, Modul 4\u202fA, (177Lu)Lutetiumvipivotidtetraxetan (Pluvicto\u00ae). www.g-ba.de\/downloads\/92-975-6353\/2022_12_20_Modul4A__177Lu_Lutetiumvipivotidtetraxetan.pdf. Accessed 6.3.2026"},{"issue":"9","key":"2817_CR29","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00120-016-0176-4","volume":"55","author":"K Miller","year":"2016","unstructured":"Miller\u00a0K et\u00a0al (2016) Metastasiertes kastrationsresistentes Prostatakarzinom. Der Urologe 55(9):1206\u20131212","journal-title":"Der Urologe"},{"issue":"2","key":"2817_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer\u00a0EA et\u00a0al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"26","key":"2817_CR31","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit\u00a0R et\u00a0al (2019) Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N\u00a0Engl J Med 381(26):2506\u20132518","journal-title":"N Engl J Med"},{"issue":"12","key":"2817_CR32","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf\u00a0DJ et\u00a0al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20(12):1730\u20131739","journal-title":"Lancet Oncol"},{"issue":"1","key":"2817_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman\u00a0MS et\u00a0al (2024) Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol 25(1):99\u2013107","journal-title":"Lancet Oncol"},{"issue":"10276","key":"2817_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS et\u00a0al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804","journal-title":"Lancet"},{"key":"2817_CR35","unstructured":"Gemeinsamer Bundesausschuss (2023) Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7\u00a035a des F\u00fcnften Buches Sozialgesetzbuch (SGB\u00a0V) (177Lu) Lutetiumvipivotidtetraxetan (Prostatakarzinom, in Kombination mit Androgendeprivationstherapie, PSMApositiv, metastasiert, kastrationsresistent, Progredienz nach Inhibition des AR-Signalwegs und taxanbasierter Chemotherapie). www.g-ba.de\/downloads\/39-261-6071\/2023-07-06_AM-RL-XII_%28177Lu%29Lutetiumvipivotidtetraxetan_D-894_BAnz.pdf. Accessed 9.3.2026"},{"key":"2817_CR36","unstructured":"EMA. Fachinfromation Lynparza. [Zugriff 06.03.2026]; www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"2817_CR37","unstructured":"EMA. Fachinformation Akeega. [Zugriff 06.03.2026]; www.ema.europa.eu\/en\/medicines\/human\/EPAR\/akeega."},{"key":"2817_CR38","unstructured":"EMA. Fachinformation Talzenna. [Zugriff 06.03.2026]; Available from: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talzenna."},{"key":"2817_CR39","doi-asserted-by":"crossref","unstructured":"Taplin, M.E., et\u00a0al., Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1. J\u00a0Clin Oncol, 2026: p. Jco2502693.","DOI":"10.1200\/JCO-25-02693"},{"issue":"10459","key":"2817_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris\u00a0MJ et\u00a0al (2024) (177)Lu-PSMA-617 versus a\u00a0change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a\u00a0phase\u00a03, randomised, controlled trial. Lancet 404(10459):1227\u20131239","journal-title":"Lancet"},{"issue":"11","key":"2817_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","volume":"36","author":"K Fizazi","year":"2025","unstructured":"Fizazi\u00a0K et\u00a0al (2025) Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol 36(11):1319\u20131330","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"2817_CR42","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1200\/JCO.2024.42.16_suppl.5083","volume":"42","author":"MO Grimm","year":"2024","unstructured":"Grimm\u00a0MO et\u00a0al (2024) Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS. Journal of Clinical Oncology 42(16_suppl):5083\u20135083","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"2817_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck\u00a0MM et\u00a0al (2019) Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA\u2011I in Metastatic Castration-resistant Prostate Cancer. Eur Urol 75(6):920\u2013926","journal-title":"Eur Urol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02817-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:57:29Z","timestamp":1777460249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02817-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02817-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.-O. Grimm gibt an: Forschungsf\u00f6rderung (institutionell und au\u00dferhalb der eingereichten Arbeit) von Bayer Vital, BMS und Intuitive Surgical; Vortragshonorare\/Reiseunterst\u00fctzung von AstraZeneca, BMS, Ipsen, MSD, Pfizer, Astellas, EUSA Pharma, Merck Serono, Bayer Vital, Janssen und Novartis; Beraterhonorare von AstraZeneca, BMS, Ipsen, MSD, Pfizer, Astellas, EUSA Pharma, Merck Serono, Roche Pharma AG, Eisai, Bayer Vital, Janssen, Gilead, Novartis und Takeda. C. Gratzke gibt an: Forschungsf\u00f6rderung von Astellas Pharma, AstraZeneca, Bayer, Janssen, MSD und STEBA Biotec; Vortragshonorare: Amgen, Astellas Pharma, AstraZeneca, Bayer, GSK, Ipsen, Janssen, Lilly Pharma, MSD und Pfizer; Reiseunterst\u00fctzung von Astellas Pharma, Bayer, Ipsen und Janssen; Beraterhonorare von Astellas Pharma, AstraZeneca, Bayer, Janssen und MSD. B. Hadaschik gibt an: Forschungsf\u00f6rderung f\u00fcr klinische Studien (IITs) von AAA\/Novartis, Bristol Myers Squibb und BMBF; Vortragshonorare\/Reiseunterst\u00fctzung von ABX, Accord, Amgen, Astellas, AstraZeneca, Bayer, Janssen R&D, Johnson&Johnson, Lightpoint, MSD, Novartis, Pfizer, StreamedUp und UroTrails; Beraterhonorare von Janssen, Bayer, ABX, Lightpoint, Amgen, MSD, Pfizer und Novartis. M. Eiber gibt an: Honorare von Blue Earth Diagnostics Ltd. (Beratung und Forschungsf\u00f6rderung), Novartis\/AAA (Berater und Referent), Telix (Berater), Bayer (Beratung und Forschungsf\u00f6rderung), RayzeBio (Berater), Point Biopharma (Berater), Eckert-Ziegler (Referent), Janssen Pharmaceuticals (Berater und Referentenb\u00fcro), Parexel (Bildauswertung) und Bioclinica (Bildauswertung), au\u00dferhalb der eingereichten Arbeit; eine Patentanmeldung f\u00fcr rhPSMA; Anspruch auf Lizenzgeb\u00fchren aus Verk\u00e4ufen zusammen mit anderen Erfindern von POSLUMA; T\u00e4tigkeit in Beir\u00e4ten und\/oder Lenkungsaussch\u00fcssen von Novartis, Blue Earth Diagnostics und Telix. K. Herrmann gibt an: Forschungsf\u00f6rderung von Advanced Accelerator Applications (a Novartis company), Boston Scientific, und Janssen; Beraterhonorare von Advanced Accelerator Applications (a Novartis company), Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien M\u00fcnchen, Janssen, Merck, MSD, Molecular Partners, NVision, POINT Biopharma, Pentixapharm, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, Theragnostics und ymabs; Patent\/Gesch\u00e4ftsanteile\/Aktien von AdvanCell, Aktis Oncology, Convergent, NVision und Sofie Biosciences. E. Hellmis gibt an: Vortrags-\/Beraterhonorare von Johnson&Johnson, Ipsen, Astellas, BMS, Roche, Astra Zeneca, Bayer Vital, Pfizer, Eisai, MSD, Recordati und Merck. J. Klier gibt an: Vortragshonorare\/Reiseunterst\u00fctzung von Johnson&Johnsen, Bayer, AstraZeneca und Astellas. G. Kristiansen gibt an: Vortragshonorare\/Reiseunterst\u00fctzung von Solution Akademie, Med publico, AstraZeneca, Jansen-Cilag, PathoTres, MSD Sharp Dohme, \u00c4rztliche Akademie f\u00fcr medizinische Fort- und Weiterbildung in Nordrhein, Landeskrebsregister NRW, Janssen Pharmaceutica NV, Novartis, APCCC Diagnostics, Janssen Sciences Ireland UC, Urologisches Tumorzentrum K\u00f6ln e.V., Onkologischer Arbeitskreis K-C-U e. V. und European Society of Pathology. A. Wiedemann gibt an: Forschungsf\u00f6rderung: Paul Kuth Stiftung, Dr. Robert Pfleger Stiftung und AMS Deutschland; Vortragshonorare von Acticore, AMS Deutschland, Apotheker-Kammer Nordrhein, Aristo, Astellas, Boston Scientific, Bayer, Der Campus, Dr. Pfleger, Ipsen, MIP Pharma, Omega Pharma und Pierre Fabre; Beraterhonorare von Dr. Pfleger, Pfizer, MIP-Pharma, Bayer, Novartis und Pierre Fabre; Patentanteile von Dr. Pfleger. A. Merseburger gibt an: Forschungsf\u00f6rderung und Studien von AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Ipsen, MSD, Merck Serono, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche; Vortragshonorare von Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche; Beraterhonorare von Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. M. Retz gibt an: Vortragshonorare von Novartis. G. von Amsberg gibt an: Forschungsf\u00f6rderung im Rahmen industriegesponserter klinischer Studien von Roche, Pfizer, BMS, MSD\/Merck, AstraZeneca, Exelixis, Ipsen, Lilly, Novartis, AvenCell, Bayer und Astellas; Honorare f\u00fcr Beratert\u00e4tigkeiten, Advisory Boards sowie f\u00fcr die Diskussion von Off-Label-Anwendungen von Amgen, Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen (Johnson & Johnson), Lilly, MSD, Merck, Novartis, Pfizer und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}